Breast cancer

Raising awareness of endocrine disruptors among young people

Retrieved on: 
Wednesday, December 21, 2022
River, Human, Breast cancer, Toxicity, Cosmetics, Endocrine disruptor, Family, Lake, INRS, Laval, Toxicology, Communication, Cell, Student, Canada Research Chair in International Political Economy, Environment, Paper, Health, Faculty, Hormone, Issue, Bouquet (EP), Pollution, Parent, Interdisciplinarity, Science, Research, Ageing, Aquaculture, Sewage, Canning, Management, Pharmaceutical industry

Valérie Langlois and Isabelle Plante, professors at the Institut national de la recherche scientifique (INRS), have been studying endocrine disruptors for many years.

Key Points: 
  • Valérie Langlois and Isabelle Plante, professors at the Institut national de la recherche scientifique (INRS), have been studying endocrine disruptors for many years.
  • Through their work, they are striving to raise public awareness of the effects that these pollutants can have on the environment and human health.
  • For these two researchers, it is essential to make young people aware of the effects of contaminants.
  • Published in 2022, the first book entitled "Rainette Explores her Wetland – The Issue of Endocrine Disruptors Explained to Our Children'' , aimed at children aged 5 to 8.

Institut Curie Study Published in a Nature Journal Reporting Excellent Outcomes of Ibex's AI Solution for Breast Cancer Detection

Retrieved on: 
Wednesday, December 21, 2022
Cloud, Atypical ductal hyperplasia, Breast cancer, DCIS, Quality of life, Curie Institute (Paris), Trial of the century, Patient, HES, Pathology, CE, H&E, Harvard Medical School, Malignancy, Mucinous carcinoma of the breast, RUO, University, AI, Diagnosis, Maccabi Healthcare Services, FDA, MD, Laboratory, Education, Bureau of Oceans and International Environmental and Scientific Affairs, Oncology, Marie Cassidy, Algorithm, Survival, TEL, Deep learning, TILS, ADH, Physician, Incidence, Research, Cancer, Artificial intelligence, UK, Medical imaging, Medical device, Nature, Ibex, Orsay

TEL AVIV, Israel, and PARIS, Dec. 21, 2022 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, and Institut Curie, France's leading cancer center, today announced excellent outcomes in a clinical study validating and evaluating the clinical application of Ibex's Galen™ Breast. The study, conducted at Institut Curie in France and at Maccabi Healthcare Services in Israel, was published in Nature's peer reviewed npj Breast Cancer journal1.

Key Points: 
  • The study, conducted at Institut Curie in France and at Maccabi Healthcare Services in Israel, was published in Nature's peer reviewed npj Breast Cancer journal1 .
  • Breast cancer is the most common malignant disease worldwide, with over 2.2 million new cases each year3.
  • The images were analyzed by Ibex's Galen Breast solution, and the AI algorithm's output was assessed against a blinded consensus diagnosis of two breast pathologists.
  • Institut Curie, France's leading cancer centre, combines an internationally renowned research centre with a cutting-edge hospital group, which treats all types of cancer, including the rarest.

An old drug represents a new hope for treating the toughest cancers

Retrieved on: 
Tuesday, December 20, 2022
Human, Breast cancer, Triple-negative breast cancer, National Cancer Institute, Patient, Overalls, Neoplasm, Radiation, Breast, Cell, Food, SAN, Gynaecology, University of Texas System, Depression, Biopsy, University, Growth, Endodontics, Diagnosis, Diabetes, FDA, Clinical trial, MD, Long School, Workforce, DNA repair, DNA, Long School of Medicine, Cancer, Survival, Obstetrics, Doctor of Philosophy, Research, UT Health San Antonio Cancer Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, University of Texas Health Science Center at San Antonio, Woman, Pharmaceutical industry, Medical imaging, Birth control, Imipramine, Medicine, Vadlamudi

SAN ANTONIO, Dec. 20, 2022 /PRNewswire-PRWeb/ -- The Mays Cancer Center at UT Health San Antonio — South Texas' only National Cancer Institute-Designated Cancer Center — is putting a decades-old antidepressant drug to new use treating breast cancers that don't respond to existing therapies.

Key Points: 
  • The discovery led to a clinical trial that benefited 15 breast cancer patients at the Mays Cancer Center.
  • Imipramine, the antidepressant, was approved by the U.S. Food and Drug Administration (FDA) in 1959 for treatment of major depressive disorder.
  • The Vadlamudi laboratory is a training ground for tomorrow's scientists — postdoctoral fellows, graduate students and younger scholars.
  • The drug also interferes with DNA repair, limiting the survival of triple-negative breast cancers.

VETERINARY LEADERS TO SHARE BREAKTHROUGHS ACROSS THE BOARD FOR MORE EFFECTIVE CANCER TREATMENT, NON-INVASIVE DIAGNOSTICS, UNDERSTANDING FELINE PAIN AND SURGERY ON THE SMALLEST PATIENTS

Retrieved on: 
Tuesday, December 20, 2022
Sentinel, Veterinarian, HDI, Textbook, HT, Health, Cat, VMX, COVID-19, Animal, News, Loyal, Epidemiology, Analgesic, Research, Sentinel (comics), Artery, Brain tumor, Patient, Weakness, MRI, Dog, Survival rate, Pandemic, Horse, Subcutaneous tissue, Risk, Bird, Veterinary medicine, Orlando Sentinel, Cancer, Hamster, Skin, Cardiology, Human, Breast cancer, Zoonosis, Family, History, Virus, American Veterinary Medical Association, Brain, Heart, Diagnosis, Life, Multimedia, Rabbit, Ageing, The Marine Mammal Center, Anesthesia, PETS, Degenerative disease, Huber loss, Trauma, Neoplasm, Vein, CT, Seizure, Orange County Convention Center, Sea, Publication, Science, Medical imaging, Dentistry, Pain

ORLANDO, Fla., Dec. 20, 2022 /PRNewswire/ -- From breast cancer surgery on a tiny hedgehog to advanced non-invasive ways to detect cancer, perform heart surgery and measure pain, the veterinary industry continues to provide new, less painful and more successful options to help animals live longer, better quality lives. This comes as good news to pet owners who see and treat their pets as family and increasingly seek the best healthcare possible for them.

Key Points: 
  • Key topics and presenters available for interviews include:
    Note: See the VMX 2023 Full Program for session dates and times.
  • Her session will focus on how the human and veterinary medical communities work together to minimize future outbreaks.
  • The North American Veterinary Community (NAVC) is a nonprofit organization dedicated to supporting and advancing veterinary professionals worldwide.
  • Since 2017, the NAVC has been recognized as one of the Top Workplaces by the Orlando Sentinel.

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries

Retrieved on: 
Tuesday, December 20, 2022
COVID-19, Psoriasis, Commonwealth, Bone loss, Suppository, Disease, Medication, Bone, MOEX, Infection, Adalimumab, NMPA, Uveitis, Woman, EMA, EEU, Patient, Hypercalcaemia, Multiple myeloma, Partnership, Rheumatoid arthritis, Marketing, Risk, FDA, Eurasian Economic Union, MA, LSE, Menopause, Twelfth, Capsule, GMP, Joint Medical Service (Germany), Prostate cancer, Breast cancer, Osteosarcoma, Gel, Fracture, National Medical Products Administration, Tablet, Osteoporosis, Malignancy, SSA, National Key Universities of Vietnam, Economic union, Crohn's disease, CIS, HCM, Ankylosing spondylitis, EU, Pharmaceutical industry, Generic drug, Medical imaging, Dentistry, Dietary supplement, Fine chemical, Denosumab

Mabwell's 9MW0321 and 9MW0311 have been filed for MA approval with the China National Medical Products Administration (NMPA) at the end of 2021.

Key Points: 
  • Mabwell's 9MW0321 and 9MW0311 have been filed for MA approval with the China National Medical Products Administration (NMPA) at the end of 2021.
  • This strategic partnership will leverage Binnopharm Group's strength as one of the biggest Russian pharmaceutical producers with significant manufacturing, registration, sales and marketing capabilities in Russia and Eurasian Economic Union countries.
  • This strategic partnership is the first to expand Mabwell's presence in Russia and Eurasian Economic Union countries, an important market for biosimilars and innovative drugs."
  • This cooperation also represents an important milestone for Binnopharm Group, and for our patients in Russia and Eurasian Economic Union countries that will ensure the social benefit from an increased access to high-quality affordable medicines."

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Retrieved on: 
Monday, December 19, 2022
Breast cancer, CDK, Trial of the century, Patient, ESR1, Gastroenterology, SERD, Food, Menarini, Progression-free survival, Fast Track, DOR, Roche, Biology, ORR, ER, FDA, Safety, Inflammation, Clinical trial, Carrick, Research and development, IND, Fulvestrant, Infection, Therapy, PFS, Analgesic, Cell cycle, Research, CDK7, Cardiology, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Development, Prostate cancer, Pharmaceutical industry

DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement.

Key Points: 
  • "We are excited to initiate this collaboration with Menarini to explore the potential of samuraciclib in combination with elacestrant for the treatment of advanced breast cancer," said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • "Our pre-clinical work and prior clinical studies have validated the biology for SERD combinations with CDK7, pointing to potential synergies when combining samuraciclib with Menarini's oral SERD, elacestrant.
  • This collaboration represents a shared commitment to maximizing the potential of novel combination therapies to improve outcomes for people living with breast cancer."
  • In addition to samuraciclib, Carrick is also developing a novel CDK12/13 inhibitor / Cyclin-K glue-degrader which has advanced into IND enabling toxicology studies.

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Retrieved on: 
Monday, December 19, 2022
Breast cancer, CDK, Trial of the century, Patient, ESR1, Gastroenterology, SERD, Food, Menarini, Progression-free survival, Fast Track, DOR, Roche, Biology, ORR, ER, FDA, Safety, Inflammation, Clinical trial, Carrick, Research and development, IND, Fulvestrant, Infection, Therapy, PFS, Analgesic, Cell cycle, Research, CDK7, Cardiology, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Development, Prostate cancer, Pharmaceutical industry

DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced a clinical trial collaboration and supply agreement.

Key Points: 
  • "We are excited to initiate this collaboration with Menarini to explore the potential of samuraciclib in combination with elacestrant for the treatment of advanced breast cancer," said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • "Our pre-clinical work and prior clinical studies have validated the biology for SERD combinations with CDK7, pointing to potential synergies when combining samuraciclib with Menarini's oral SERD, elacestrant.
  • This collaboration represents a shared commitment to maximizing the potential of novel combination therapies to improve outcomes for people living with breast cancer."
  • In addition to samuraciclib, Carrick is also developing a novel CDK12/13 inhibitor / Cyclin-K glue-degrader which has advanced into IND enabling toxicology studies.

Anixa Biosciences to Present at Biotech Showcase 2023

Retrieved on: 
Monday, December 19, 2022
Cleveland Clinic, Breast cancer, H. Lee Moffitt Cancer Center & Research Institute, Protein, Sumathi Best Television Current Reporting Award, Annual report, SAN, Biotechnology, Hilton San Francisco Union Square, Ovarian cancer, Cancer, TNBC, Infection, Risk, Disease, Severe acute respiratory syndrome coronavirus 2, COVID-19, Therapy, Mpro, Pharmaceutical industry

SAN JOSE, Calif., Dec. 19, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.

Key Points: 
  • SAN JOSE, Calif., Dec. 19, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.
  • Biotech Showcase is one of the industry's largest annual healthcare investor and partnering conferences, bringing together biopharmaceutical and life sciences company executives, investors, sector analysts, bankers, and industry stakeholders.
  • More than 350 presentations from mid-, small- and micro-cap public and private companies are expected to present at the event.
  • Qualified investors and buy- and sell-side analysts are invited to request a complimentary registration to attend Biotech Showcase.

IDEAYA Biosciences Appoints Dr. Karlene Cimprich, Ph.D. and Dr. Kornelia Polyak, M.D., Ph.D. to Scientific Advisory Board

Retrieved on: 
Monday, December 19, 2022
ADP, Breast cancer, Science, Coronavirus Scientific Advisory Board (Turkey), DNA replication, McCormick, Drug discovery, Stanford Cancer Institute, UCSF, SAN, Therapy, National academy, National Academy of Medicine, University of California, San Diego, DNA, MIT, San Francisco, Stanford University School of Medicine, NCI-designated Cancer Center, San Diego, Cancer Institute, Patient, Harvard University, Systems biology, Research, University of Washington, Biomarker, Precision medicine, Harvard Medical School, University, Senior, Dana–Farber Cancer Institute, COVID-19, PARG, Pharmaceutical industry, DRS, Medicine

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Dr. Karlene Cimprich, Ph.D., and Dr. Kornelia Polyak, M.D., Ph.D., to its Scientific Advisory Board. 

Key Points: 
  • Her work is relevant to IDEAYA's potential first-in-class pipeline programs in synthetic lethality DNA Damage Repair.
  • IDEAYA plans to clinically evaluate IDE161, its potential first-in-class inhibitor of poly (ADP-ribose) glycohydrolase (PARG), as monotherapy, including in BRCA1/2-mutant breast cancer patients.
  • Cimprich and Polyak as we continue to expand the breadth and depth of medical and scientific expertise on the IDEAYA Scientific Advisory Board.
  • "Our Scientific Advisory Board is integral to advancing our synthetic lethality programs.

Olympus Announces Launch of Olympus Asia Pacific Innovation Program

Retrieved on: 
Monday, December 5, 2022
Breast cancer, Quality of life, Management of prostate cancer, Laparoscopy, Health, Incidence, Colon, Medicine, Endoscopy, Lung, Stomach, Growth, Cancer, Military Medical Business, Automotive Supplier Innovation Program, Patient, Medtech, Medical imaging, Pharmaceutical industry, Online shopping, Dentistry, Medical device

As part of Olympus' dedication to continuing its history of innovation, Olympus is proud to announce the inaugural Olympus Asia Pacific Innovation Program (OAIP).

Key Points: 
  • As part of Olympus' dedication to continuing its history of innovation, Olympus is proud to announce the inaugural Olympus Asia Pacific Innovation Program (OAIP).
  • Olympus believes that the emergence of new technologies, particularly those within the digital realm, will revolutionize the patient care paradigm.
  • Felicia Chung, Olympus Business Development Leader for the Asia Pacific region said "I am pleased to announce Olympus' first-ever Innovation Program that seeks to identify and collaborate with innovators in the very exciting medtech space.
  • Marc Radatt, CEO for Olympus Corporation of Asia Pacific Limited and board member of the Asia Pacific Medical Technology Association (APACMed), said "Olympus is proud to have partnered with MedTech Innovator Asia Pacific in pursuit of new ideas that will revolutionize patient outcomes and increase access to new technologies through the OAIP.